After a mean follow-up of 23 mo ( PHiD-CV , n = 10,295 ; control , n = 10,201 ) , per-protocol VE was 22.0 % ( 95 % CI : 7.7 , 34.2 ; one-sided p = 0.002 ) against B-CAP ( conclusive for primary objective ) and 25.7 % ( 95 % CI : 8.4 % , 39.6 % ) against World Health Organization-defined consolidated CAP .